TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06041321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reparel Sleeve
Description: For the purpose of this study, the Reparel Sleeve will be evaluated against a placebo sleeve of similar feel, texture, and look. The indication is that due to its technology, the Reparel sleeve will allow for the ability to reflect energy using a blend of semi-conductors grounded to nanoparticles interwoven between fibers of the sleeve. Thermal energy is then absorbed from the patient thus activating electrons on the nanoparticles and releasing photonic energy directed at tissues within the surrounding area7. This photostimulation is expected to alleviate pain and inflammation while promoting wound healing as well as tissue regeneration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sleeve
Description: Generic sleeve used as a placebo. This placebo will have a similar feel, texture, and look with no additional technology.
Study: NCT05962021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Chemotherapy
Description: Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab plus Chemotherapy
Description: Therapy was administered on a 21-day regimen for 3 cycles, with Toripalimab (240mg, d1), carboplatin (AUC=5, d1) + pemetrexed (500 mg/m2, d1) for patients with lung adenocarcinoma and carboplatin (AUC=5, d1) + albumin-bound paclitaxel (260 mg/m2, d1) for patients with other subtypes.
Study: NCT05786287

Intervention type: BIOLOGICAL
Intervention: Conditioned Medium (CM)
Description: Conditioned Medium (CM) injected by peribulbar
Study: NCT05607017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Taken Orally
Study: NCT05607017

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Photon Radiation Therapy
Study: NCT06224881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ascorbic acid
Description: 2 gm every 8hrs for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic acid
Description: 2 gm every 8hrs for 4 days
Study: NCT05786287

Intervention type: BIOLOGICAL
Intervention: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Description: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar

Intervention type: BIOLOGICAL
Intervention: Umbilical Cord Mesenchymal Stem Cell (UC-MSC)
Description: Umbilical Cord Mesenchymal Stem Cell (UC-MSC) injected by peribulbar
Study: NCT03567694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA115
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA115
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT04956757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Scapula retraction exercises at varying shoulder abduction angles will be applied
Study: NCT04679454

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase I
Description: To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase II
Description: The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
Study: NCT04863430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg oral qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
Study: NCT05152472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg
Description: (Intravenous administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib 400 MG
Description: (Per os)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib 400 MG
Description: (Per os)
Study: NCT05890287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide+ exemestane/Fulvestrant/Letrozole/Anastrozole/Tamoxifen
Study: NCT04423614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Breathing
Description: Relaxation breathing exercises, performed 5 times a week for 2-4 weeks prior to cardiac surgery.
Study: NCT05671601

Intervention type: DIAGNOSTIC_TEST
Intervention: Automatic picture recognition
Description: A machine that processes photographs automatically taken

Intervention type: DIAGNOSTIC_TEST
Intervention: Manual Assessment Group
Description: Manual recognition of pictures
Study: NCT05059418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonazepam 0.5 MG
Description: Topical treatment of oral mucosa with lozenge pill

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical
Description: Topical treatment of oral mucosa with capsaicin rinse

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouth rinse with no capsaicin
Study: NCT00608816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
Study: NCT04773665

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2902a
Description: VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2902a
Description: VBI-2902a is an intramuscular injection of VBI-2902a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VBI-2905a
Description: VBI-2905a is an intramuscular injection of VBI-2905a investigational enveloped virus-like particle COVID-19 vaccine with aluminum phosphate adjuvant.
Study: NCT05460182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF+CTG
Description: Coronally Advanced Flap + Connective Tissue Graft
Study: NCT04913779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-SARS-CoV-2
Description: Purified F(ab')2 Fragments of Equine hyperimmune Serum with anti-SARS-CoV-2 neutralizing activity (titer 1/5120 or higher)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 10 ml of a control-solution without neutralizing activity against SARS-CoV-2, administered in slow intravenous infusion (10 ml diluted in 100 ml of saline solution, administered over 50 to 60 minutes in slow drip), produced by ANLIS-Malbrán, administered twice (time 0 when incorporated into the study -initial dose- and at 48 hours -second dose-).
Study: NCT05460182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAF
Description: Coronally Advanced Flap
Study: NCT04675827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab and tratuzumab fixed dose combination
Description: Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Treatment administration: adjuvant T-DM1 for 14 cycles.
Study: NCT06476678

Intervention type: DEVICE
Intervention: Speedboat™ Ultraslim
Description: Use of Speedboat™ Ultraslim for performing endoscopic submucosal dissection of esophageal lesions.
Study: NCT05559099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tecovirimat Oral Capsule
Description: 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules to match tecovirimat
Study: NCT03827941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Hz Auricular transcutaneous electrical nerve stimulation
Description: High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20 Hz Auricular transcutaneous electrical nerve stimulation
Description: High-functioning individuals with autism randomized to this group will receive 1 Hz tVNS stimulation for 30 minutes/day up to 5 times/week for 3 weeks.
Study: NCT05497141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System
Description: Subjects who received Neoblazar® Transcatheter Tricuspid Valve Edge-to Edge Repair System will be included in this arm. The Neoblazar® is intended for reconstruction of the insufficient tricuspid valve through tissue tissue approximation.
Study: NCT04620915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-level construal
Description: In the high-level construal condition, participants will be sent messages asking them to consider why they are quitting (What are your main reasons for quitting?) and to imagine what their lives will look like in the future if they succeed (What would quitting mean to you and your family's future?; Yeager et al., 2014). The corpus for this condition is 100 messages composed by a large independent sample of mTurk workers who are smokers and validated by a team of RAs trained to 0.8 reliability on ratings of high-level construal. To meet criteria for inclusion, a message must be rated as significantly closer to high-level (vs. low-level) on a rating scale of construal level.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Down-regulation of craving for cigarettes
Description: In the down-regulation of craving condition, participants will be sent messages that encourage inhibitory control of cravings for cigarettes (e.g., using cognitive reappraisal or attentional control) and that provide strategies to do so (e.g., When you feel an urge to smoke, think about the health consequences). The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability on ratings of plausibility AND effortful cognitive inhibition or control.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics with a custom, personalized link sent to the participant via email and text.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up-regulation of goal energization
Description: In the up-regulation of goal energization condition, participants will be sent messages that encourage them to consider the core values that drive their desire to quit smoking. These messages will name a specific core value that the participant rated in the top three (of 19) during the baseline session, and will draw a connection between quitting and the core value. For example, a message for a person who nominated family as one of her top three core values might read, Quitting will help you model a healthy lifestyle for your family. This intervention is grounded in robust theory and evidence supporting Self-Affirmation Theory. The corpus for this condition is 100 messages composed by a large, independent sample of mTurk smokers and validated by a team of RAs trained to 0.8 reliability in correctly identifying to which core value the message is tied.~In addition to the texting, participants will complete biweekly online booster sessions using Qualtrics.
Study: NCT06148896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GrExPACT
Description: Combining physiotherapy group exercise with acceptance and commitment therapy delivered by physiotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GrEx
Description: Group physiotherapy exercise
Study: NCT05364905

Intervention type: DRUG
Intervention: Chemotherapy
Description: Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.

Intervention type: DRUG
Intervention: Chemotherapy
Description: Patients with confirmed advanced, recurrent or metastatic endometrial cancer, treated by chemotherapy in real life-setting, between 1st January 2019 to 31rd December March 2019, in first or second line of chemotherapy.
Study: NCT06225388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression socks
Description: A pair of socks corresponding to the intervention allocated will be given to the participant, by an investigator who will not participate in the evaluation, in a dark plastic bag to avoid any visual influence. We will adopt strategies to prevent information about the socks from influencing the participants' behaviour: (1) the compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo socks
Description: The compression and placebo socks will have the same colour, any visual detail and branding will be covered. Words or logos from the compression sock will be covered, so participants are unable to differentiate them. (2) After performing the running protocol, participants will remove their socks and return them to the investigator.
Study: NCT05887180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PräVaNet-Intervention
Description: interdisciplinary and digitally supported prevention concept
Study: NCT05625334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: powder for oral inhalation via a Dry Powder Inhaler (DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: powder for oral inhalation via a Dry Powder Inhaler (DPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-enteric-coated chewable aspirin
Description: Orally administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-enteric-coated chewable aspirin
Description: Orally administered
Study: NCT05099263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivaer Arc Stylus
Description: The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal airway in a single study session.
Study: NCT05448807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OraVerse
Description: Phentolamine mesylate is a vaso-dilator that was used for treating dermal necrosis and severe hypertension cases since 1952. It is alpha-adrenergic antagonist. Oraverse is supplied in a dose equal to the amount of LA taken in adults and children with weights more than 30 kg. While in children less than 30 kg, it is advised to use only half carpule according the manufacturer's instructions.
Study: NCT04834973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigilanol tiglate
Description: Single or multiple Intratumoural treatment of tigilanol tiglate at escalating doses of 0.6 mg/m2, 1.2 mg/m2 and 2.4 mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Three weekly 200 mg intravenous pembrolizumab treatment.~Pembrolizumab is a systemic anti-programmed cell death receptor 1 (PD 1) immunotherapy.
Study: NCT04830800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC
Description: COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC
Description: COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC
Description: COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVIVAC
Description: COVIVAC vaccine, manufactured by IVAC with or without adjuvant CpG1018 for prevention of COVID-19

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate-buffered saline
Description: Phosphate buffer solution (pH 7.2), manufactured by IVAC
Study: NCT05881772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation
Description: It will be applied a dose of laser radiation through a cluster with four diodes, wavelength of 830 nm and power of 800mW (200mW/diode), HTM® (model Fluence MAXX, São Paulo, Brazil). For application, the patient will be positioned in a sitting position and the treatment will be performed with the fixed probe in contact with the skin at an angle of 90º, using the continuous emission mode. The therapy will be applied to the quadriceps muscle, bilaterally.
Study: NCT04765137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Oral Tablet
Description: Atorvastatin pill 40 mg to be taken every night
Study: NCT04549532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Multidomain
Description: Participants in the T-MD intervention group will be prescribed targeted interventions to address each individual's symptoms, impairments, and functional limitations in the areas of anxiety/mood, cognitive, migraine/headache, ocular, vestibular, sleep, autonomic. The length of the intervention period will be 4 weeks or until RTA, whichever comes first.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Management
Description: 1.3. Usual Care (Controls) Group Participants randomized to the usual care (control) group will receive standardized (i.e., all participants in this group will receive the same interventions) behavioral management strategies that include activity, hydration, nutrition, sleep, and stress management strategies.
Study: NCT05220215

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic Hamstring Exercise
Description: To perform Nordic Hamstring Exercise, the subject was in kneeling position on the mat, arms by the side or in front of the chest, knee in 90-degree flexion and ankles well stabilized with the help of a therapist which is positioned behind the subject. Then subject was asked to lean forward by using the hamstring muscles by extending while trying to resist the forward fall, he should lean forward from the knee and not from the hip. The only time one can put his hands in front of him is when he can't rely on his legs and then push himself back to starting position and them repeat the procedure again.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring Curl with Resistance band
Description: Traditional Hamstring Curl by using Resistance band.~Resistance Band: Thera-band Green, 4.6 kg resistance at 100% elongation